含紫杉类药物联合治疗中晚期恶性肿瘤37例  

Effect of taxol based combined chemotherapy on 37 cases of advanced malignant tumor

作　　者：郑玉君[1] 郝祝华[1] 路霞[1] 杨莲[1] 

机构地区：[1]大连市中心医院

出　　处：《中国肿瘤临床与康复》2000年第3期87-88,共2页Chinese Journal of Clinical Oncology and Rehabilitation

摘　　要：目的　观察含紫杉类药物的联合化疗对晚期恶性肿瘤的临床疗效及安全性。方法　用含紫杉类药物 (紫杉醇Paclitaxel,泰索帝Taxotere)的联合化疗方案治疗 3 7例中晚期恶性肿瘤患者 ,可评价疗效者 3 6例 ,其中非小细胞肺癌 (NSCLC) 11例 ,小细胞肺癌 (SCLC) 3例 ,乳腺癌 15例 ,胃癌 2例 ,大肠癌 5例。结果　CR 3例 ,PR 14例 ,SD 13例 ,PD 6例 ,总有效率 47.2 % ,WBC下降占 91.7% ,脱发占 88.9% ,肌肉关节痛占 69.4% ,指趾麻木占 5 8.3 %。结论　紫杉类药物对NSCLC ,乳腺癌 ,大肠癌及伴有肝转移的恶性肿瘤有较高的疗效 。? Objective To observe the effect of taxol based combined chemotherapy on malignant tumors.Methods 36 cases received paclitaxel or taxotere based chemotherapy,including 11 NSCLC,3 SCLC,15 breast cancer,2 gastric cancer,5 colorectal cancer.Results The response rate was 47.2% including 3 CR, 14 PR, 13 SD,6 PD,with 91.7% of leukopenia,88.9% alopecia,69.4% of myodynia and arthrodynia,58.3% of finger and digiti numbness.Conclusions A high response rate with tolerated toxicity of paclitaxel or taxotere based regiman could be observed in treating NSCLC,breast cancer,colorectal cancer and malignancies with hepatic metastasis. 〔

关 键 词：紫杉类药物 中晚期恶性肿瘤 

分 类 号：R730.5[医药卫生—肿瘤]